Amgen, Sandoz Ask Federal Circuit For En Banc Review Of Zarxio Case
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen argues that a biosimilar applicant's ability to file an infringement suit does not make the statutory requirement to provide information to the BLA sponsor optional; Sandoz says statute does not provide BLA sponsor extra six months of exclusivity.